SPP1 and plasma cell myeloma: Furthermore, CM-272 treatment was able to upregulate the relative expression of several late bone formation markers (namely, bone siaploprotein, osteopontin, and osteocalcin) in MSCs from myeloma patients (Fig. 4H).